190 related articles for article (PubMed ID: 30157297)
1. Myeloproliferative neoplasms in the young: Mayo Clinic experience with 361 patients age 40 years or younger.
Szuber N; Vallapureddy RR; Penna D; Lasho TL; Finke C; Hanson CA; Ketterling RP; Pardanani A; Gangat N; Tefferi A
Am J Hematol; 2018 Dec; 93(12):1474-1484. PubMed ID: 30157297
[TBL] [Abstract][Full Text] [Related]
2. Clinical Manifestations and Risk Factors for Complications of Philadelphia Chromosome-Negative Myeloproliferative Neoplasms.
Duangnapasatit B; Rattarittamrong E; Rattanathammethee T; Hantrakool S; Chai-Adisaksopha C; Tantiworawit A; Norasetthada L
Asian Pac J Cancer Prev; 2015; 16(12):5013-8. PubMed ID: 26163633
[TBL] [Abstract][Full Text] [Related]
3. 3023 Mayo Clinic Patients With Myeloproliferative Neoplasms: Risk-Stratified Comparison of Survival and Outcomes Data Among Disease Subgroups.
Szuber N; Mudireddy M; Nicolosi M; Penna D; Vallapureddy RR; Lasho TL; Finke C; Begna KH; Elliott MA; Hook CC; Wolanskyj AP; Patnaik MM; Hanson CA; Ketterling RP; Sirhan S; Pardanani A; Gangat N; Busque L; Tefferi A
Mayo Clin Proc; 2019 Apr; 94(4):599-610. PubMed ID: 30824279
[TBL] [Abstract][Full Text] [Related]
4. Genetic Risk Assessment in Myeloproliferative Neoplasms.
Tefferi A; Vannucchi AM
Mayo Clin Proc; 2017 Aug; 92(8):1283-1290. PubMed ID: 28778261
[TBL] [Abstract][Full Text] [Related]
5. Coexisting JAK2V617F and CALR Exon 9 Mutations in Myeloproliferative Neoplasms - Do They Designate a New Subtype?
Ahmed RZ; Rashid M; Ahmed N; Nadeem M; Shamsi TS
Asian Pac J Cancer Prev; 2016; 17(3):923-6. PubMed ID: 27039813
[TBL] [Abstract][Full Text] [Related]
6. [Clinical Analysis of Driver Mutations in Patients with Ph Negative Myeloproliferative Neoplasms].
He ZP; Tian HY; Tan M; Wu Y
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2018 Jun; 26(3):842-848. PubMed ID: 29950230
[TBL] [Abstract][Full Text] [Related]
7. Calreticulin exon 9 mutations in myeloproliferative neoplasms.
Ha JS; Kim YK
Ann Lab Med; 2015 Jan; 35(1):22-7. PubMed ID: 25553276
[TBL] [Abstract][Full Text] [Related]
8. Changing incidence of myeloproliferative neoplasms: trends and subgroup risk profiles in the USA, 1973-2011.
Deadmond MA; Smith-Gagen JA
J Cancer Res Clin Oncol; 2015 Dec; 141(12):2131-8. PubMed ID: 25968903
[TBL] [Abstract][Full Text] [Related]
9. Changing concepts of diagnostic criteria of myeloproliferative disorders and the molecular etiology and classification of myeloproliferative neoplasms: from Dameshek 1950 to Vainchenker 2005 and beyond.
Michiels JJ; Berneman Z; Schroyens W; De Raeve H
Acta Haematol; 2015; 133(1):36-51. PubMed ID: 25116092
[TBL] [Abstract][Full Text] [Related]
10. TERT rs2736100 A>C SNP and JAK2 46/1 haplotype significantly contribute to the occurrence of JAK2 V617F and CALR mutated myeloproliferative neoplasms - a multicentric study on 529 patients.
Trifa AP; Bănescu C; Tevet M; Bojan A; Dima D; Urian L; Török-Vistai T; Popov VM; Zdrenghea M; Petrov L; Vasilache A; Murat M; Georgescu D; Popescu M; Pătrinoiu O; Balea M; Costache R; Coleș E; Șaguna C; Berbec N; Vlădăreanu AM; Mihăilă RG; Bumbea H; Cucuianu A; Popp RA
Br J Haematol; 2016 Jul; 174(2):218-26. PubMed ID: 27061303
[TBL] [Abstract][Full Text] [Related]
11. [Diagnosis and treatment of BCR/ABL-negative myeloproliferative diseases--principles and rationale of CZEMP recommendations].
Schwarz J; Penka M; Campr V; Pospísilová D; Kren L; Nováková L; Bodzásová C; Brychtová Y; Cerná O; Dulícek P; Joniásová A; Kissová J; Korístek Z; Schützová M; Vonke I; Walterová L
Vnitr Lek; 2011 Feb; 57(2):189-213. PubMed ID: 21416861
[TBL] [Abstract][Full Text] [Related]
12. Patient characteristics and outcomes in adolescents and young adults with classical Philadelphia chromosome-negative myeloproliferative neoplasms.
Boddu P; Masarova L; Verstovsek S; Strati P; Kantarjian H; Cortes J; Estrov Z; Pierce S; Pemmaraju N
Ann Hematol; 2018 Jan; 97(1):109-121. PubMed ID: 29143068
[TBL] [Abstract][Full Text] [Related]
13. Epidemiology and clinical relevance of mutations in postpolycythemia vera and postessential thrombocythemia myelofibrosis: A study on 359 patients of the AGIMM group.
Rotunno G; Pacilli A; Artusi V; Rumi E; Maffioli M; Delaini F; Brogi G; Fanelli T; Pancrazzi A; Pietra D; Bernardis I; Belotti C; Pieri L; Sant'Antonio E; Salmoiraghi S; Cilloni D; Rambaldi A; Passamonti F; Barbui T; Manfredini R; Cazzola M; Tagliafico E; Vannucchi AM; Guglielmelli P
Am J Hematol; 2016 Jul; 91(7):681-6. PubMed ID: 27037840
[TBL] [Abstract][Full Text] [Related]
14. Application of an NGS-based 28-gene panel in myeloproliferative neoplasms reveals distinct mutation patterns in essential thrombocythaemia, primary myelofibrosis and polycythaemia vera.
Delic S; Rose D; Kern W; Nadarajah N; Haferlach C; Haferlach T; Meggendorfer M
Br J Haematol; 2016 Nov; 175(3):419-426. PubMed ID: 27447873
[TBL] [Abstract][Full Text] [Related]
15. The Epidemiology of Myeloproliferative Neoplasms in New Zealand between 2010 and 2017: Insights from the New Zealand Cancer Registry.
Varghese C; Immanuel T; Ruskova A; Theakston E; Kalev-Zylinska ML
Curr Oncol; 2021 Apr; 28(2):1544-1557. PubMed ID: 33919650
[TBL] [Abstract][Full Text] [Related]
16. [Clinical Analysis of 208 Patiets with BCR/ABL Negative Myeloproliferative Neoplasms].
Shen QH; Guo YJ; Xue CE; Wang Y; Lin FR
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2019 Feb; 27(1):159-164. PubMed ID: 30738463
[TBL] [Abstract][Full Text] [Related]
17. Multicenter Retrospective Analysis of Turkish Patients with Chronic Myeloproliferative Neoplasms.
Soyer N; Haznedaroğlu İC; Cömert M; Çekdemir D; Yılmaz M; Ünal A; Çağlıyan G; Bilgir O; İlhan O; Özdemirkıran F; Kaya E; Şahin F; Vural F; Saydam G
Turk J Haematol; 2017 Mar; 34(1):27-33. PubMed ID: 27094252
[TBL] [Abstract][Full Text] [Related]
18. Dkk3 levels in patients with myeloproliferative neoplasms.
Medinger M; Muesser P; Girsberger S; Skoda R; Tzankov A; Buser A; Passweg J; Tsakiris DΑ
Thromb Res; 2014 Feb; 133(2):218-21. PubMed ID: 24309205
[TBL] [Abstract][Full Text] [Related]
19. Thrombotic and hemorrhagic events in 2016 World Health Organization-defined Philadelphia-negative myeloproliferative neoplasm.
Song IC; Yeon SH; Lee MW; Ryu H; Lee HJ; Yun HJ; Kim SY; Jo DY
Korean J Intern Med; 2021 Sep; 36(5):1190-1203. PubMed ID: 34289585
[TBL] [Abstract][Full Text] [Related]
20. Changes in the incidence and overall survival of patients with myeloproliferative neoplasms between 2002 and 2016 in the United States.
Verstovsek S; Yu J; Scherber RM; Verma S; Dieyi C; Chen CC; Parasuraman S
Leuk Lymphoma; 2022 Mar; 63(3):694-702. PubMed ID: 34689695
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]